



EFFECTS OF *EURYCOMA LONGIFOLIA*  
STANDARDIZED EXTRACT ON FEMALE  
REPRODUCTIVE DISPOSITION AND PERTURBATION  
PATHWAYS IN FEMALE RATS

BY

NUR AMALINA BINTI AHMAD

A thesis submitted in fulfilment of the requirement for the  
degree of Doctor of Philosophy (Health Sciences)

Kulliyyah of Allied Health Science  
International Islamic University Malaysia

MAY 2019

## ABSTRACT

*Eurycoma longifolia* is a traditional plant that has long been used for enhancement of male reproductive functions by enhancement of male testosterone levels thus improving the spermatogenesis process. However, effects of *E. longifolia* on the female reproductive functions are lacking and have yet to be elucidated. The present work was performed to investigate the potential and beneficial effects of *E. longifolia* standardized extract, TAF 273, on female reproductive functions and abnormalities. The effects of TAF 273 were investigated in normal female rats and estradiol valerate-induced polycystic ovarian condition rats as well as foetal development and teratogenicity conditions in female rats. Effects of TAF 273 on normal female rats were assessed in female Sprague-Dawley rats, aged between 8 to 10 weeks old. Animals were orally treated with 2.5, 5, 10, 25, 50 and 100 mg/kg of TAF 273 over 5 and 14 days. Oestrous cycle and levels of reproductive hormones were then evaluated together with the histomorphological changes in the ovaries. Similar sets of animals were used for induction of polycystic ovarian syndrome (PCOS) by a single subcutaneous dose of 2 mg estradiol valerate per rat. Rats with vaginal cornification at the end of 60 days were taken to be successfully induced. Treatments with Clomiphene citrate and TAF 273 were administered orally daily for 28 days. The hormonal levels were then measured followed by assessment of histomorphology of the ovary. Steroidogenesis-related genes and proteins (CYP11A1, CYP17A1 and CYP19A1) were also examined in histological paraffin sections using HRP-DAB method and quantitative RT-PCR. Evaluation of foetal development and teratogenicity was done by administration of a single subcutaneous injection of 0.15 mg/kg of estradiol valerate to dams on day 12 of gestation and concurrent treatment with TAF 273 (25, 50 and 100 mg/kg) from day 12 to day 19 of gestation. Foetal assessment was conducted following termination of pregnancy at day 21. The administration of TAF 273 extract did not significantly alter the oestrous cycle of the rats during the 5 and 14 days of treatment which was supported by normal levels of the reproductive hormones as well as normal morphology of the ovaries. TAF 273 extract at a dose of 100 mg/kg also possess beneficial effects in improvement of PCO by improving the ovarian morphology as evident by the presence of more abundant healthy follicles as opposed to cystic follicles and the occurrence of corpora lutea as an indication of ovulation. Hormonal imbalances and expressions of steroidogenic genes were also found to be attenuated probably through its action on oestradiol hormones and CYP19A1 gene. A higher potency of abortion and foetus showing abnormalities in external morphology was observed in female dams exposed to estradiol valerate on GD12. The number of live foetuses in dams treated with 100 mg/kg TAF 273 extract increased but with decreased body weight and crown-rump length of the foetuses. Foetuses with malformations in the form of kyphosis, scoliosis and kinky tail were more pronounced in EV group compared to the control and TAF 273-treatment groups. In conclusion, results obtained showed that the *E. longifolia* standardized extract, TAF 273, has the potential in maintaining normal functions of the female reproductive system and it may have economic value in the management of female disorders and reproductive health.

## خلاصة البحث

إن يوريكوما لونجفوليا (*Eurycoma longifolia*) هو نبات تقليدي يستخدم منذ القدم لتعزيز وظائف الإنجاب للذكور من خلال تعزيز مستويات هرمون التستوستيرون الذكوري وبالتالي تحسين عملية إنتاج الحيوانات المنوية. ومع ذلك، فإن آثار يوريكوما لونجفوليا على وظائف الإنجاب الأنثوية غير موجودة ولم يتم توضيحها بعد. وقد تم الاضطلاع بهذا العمل لمعرفة الآثار المحتملة والمفيدة من مستخلص يوريكوما لونجفوليا ، TAF 273، على وظائف الإنجاب للإناث. تم التحقق من آثار TAF 273 على إناث الفئران العادية وفئران معالجة باستراديول فاليرات التي تسبب حالة تكيس في المبايض وكذلك تؤثر على تطور الجنين والظروف المسخية في إناث الفئران. تم تقييم تأثير TAF 273 على إناث الفئران العادية سبراغ-داولي، الذين تتراوح أعمارهم بين 8 إلى 10 أسابيع من العمر. تم علاج الحيوانات عن طريق الفم مع 2.5، 5، 10، 25، 50 و 100 ملغ / كغ من TAF 273 على مدى 5 و 14 يوما. ثم تم تقييم دورة المهبل ومستويات الهرمونات الإنجابية جنبا إلى جنب مع التغيرات الهيستومورفولوجية في المبايض. تم استخدام مجموعات مماثلة من الحيوانات لتحريض متلازمة المبايض المتعدد الأكياس مع حقن واحد تحت الجلد من استراديول فاليرات (2 ملغ / فأر). وقد أخذت الفئران كورنفيكاتيون بالمهبل بعد نهاية ستين يوما لتكون عملية الحقن ناجحة. العلاجات مع كلوميفين سترات و TAF 273 كانت تدار عن طريق الفم يوميا لمدة 28 يوما. ثم تم قياس مستويات الهرمونات تليها تقييم هيستومورفولوجيا المبيض. كما تم فحص الجينات والبروتينات ذات الصلة بالستيرويد CYP11A1، CYP17A1 و CYP19A1 في أقسام البارافين النسيجية باستخدام طريقة HRP-DAB والكمية RT-PCR. وقد تم تقييم تطور الجنين والمسوخ عن طريق إعطاء حقن تحت الجلد واحد من 0.15 ملغ / كغ من فاليرات استراديول في يوم 12 من الحمل والعلاج المتزامن مع TAF 273 (25، 50 و 100 ملغ / كلغ) من يوم 12 إلى يوم 19 من الحمل. أجري تقييم الجنين بعد إنهاء الحمل في اليوم 21. بعد استخراج TAF 273 لم يغير كثيرا علي الدورة الشهرية للفئران خلال 5 و 14 يوما من العلاج الذي كان مدعوما من المستويات العادية للهرمونات التناسلية وكذلك بطبيعة مورفولوجيا المبيض. اعطاء مستخلص TAF 273 بجرعة 100 ملغ / كغ التي لها أيضا آثارا مفيدة في تحسين تكيس المبايض من خلال تحسين مورفولوجيا المبيض كما يتضح من وجود بصيلات صحية أكثر وفرة بدلا من بصيلات الكيس المبيضي وتكون الجسم الأصفر كمؤشر للإباضة. كما وجد أن الاختلالات الهرمونية وتعبيرات الجينات الستيرويدية قد قلت على الأرجح من خلال عملها على هرمونات الاستراديول وجين CYP19A1 وقد أظهر التعرض لاستراديول فاليرات لإناث الفئران فعالية عالية من الإجهاض مع العيوب الخارجية لتشكيل الجنين. أظهرت الأجنة في المجموعة المعالجة ب 100 ملغم / كغم من مستخلص TAF 273 عددا كبيرا من الأجنة الحية ولكن مع انخفاض وزن وطول الجسم. وكانت الملاحظات من تشوهات في شكل محدب ومقوس للذيل في مجموعة EV أكثر وضوحا مما كانت عليه في مجموعة المقارنة والعلاجات. في الختام، أظهرت النتائج التي تم الحصول عليها أن مستخلص يوريكوما لونجفوليا موحد، TAF 273، لديه القدرة على الحفاظ على الوظائف العادية للجهاز التناسلي الأنثوي وقد يكون لها قيمة اقتصادية في إدارة اضطرابات الإناث والصحة الإنجابية.

## **APPROVAL PAGE**

The thesis of Nur Amalina Ahmad has been approved by the following:

---

Associate Prof. Dr. Suzanah Abdul Rahman  
Supervisor

---

Assistant Prof. Dr. Suhana Mamat  
Co-Supervisor

---

Assistant Prof. Dr. Muhammad Rusdi Ahmad Rusmili  
Internal Examiner

---

Prof. Dr. Ahmad Rohi Ghazali  
External Examiner

---

Associate Prof. Dr. Mahaneem Mohamed  
External Examiner

---

Prof. Dr. Ahmed Jalal Khan Chowdhury  
Chairman

## **DECLARATION**

I hereby declare that this dissertation is the result of my own investigations, except where otherwise stated. I also declare that it has not been previously or concurrently submitted as a whole for any other degrees at IIUM or other institutions.

Nur Amalina Ahmad

Signature .....

Date .....

**INTERNATIONAL ISLAMIC UNIVERSITY MALAYSIA**

**DECLARATION OF COPYRIGHT AND AFFIRMATION OF  
FAIR USE OF UNPUBLISHED RESEARCH**

**EFFECTS OF *EURYCOMA LONGIFOLIA* STANDARDIZED  
EXTRACT ON FEMALE REPRODUCTIVE DISPOSITION AND  
PERTURBATION PATHWAYS IN FEMALE RATS**

I declare that the copyright holders of this dissertation are jointly owned by the student and IIUM.

Copyright © 2019 Nur Amalina Ahmad and International Islamic University Malaysia. All rights reserved.

No part of this unpublished research may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise without prior written permission of the copyright holder except as provided below

1. Any material contained in or derived from this unpublished research may be used by others in their writing with due acknowledgement.
2. IIUM or its library will have the right to make and transmit copies (print or electronic) for institutional and academic purposes.
3. The IIUM library will have the right to make, store in a retrieved system and supply copies of this unpublished research if requested by other universities and research libraries.

By signing this form, I acknowledged that I have read and understand the IIUM Intellectual Property Right and Commercialization policy.

Affirmed by Nur Amalina Ahmad

.....  
Signature

.....  
Date

## ACKNOWLEDGEMENTS

With the name of Allah, Most Gracious, Most Merciful.

I would like to express my deepest and sincere gratitude to my supervisor, Associate Professor Dr. Suzanah Abdul Rahman, for her supervision and guidance from the beginning of my journey. Thank you for being patient with me throughout the years. I would also like to thank Assistant Professor Dr. Suhana Mamat and Professor Chan Kit Lam for their co-supervisions and valuable advices on my work.

I take this opportunity to express my gratitude to the people who have been contributing in the successful completion of this project. My utmost appreciation to my team mate and best friend, Sr. Nadia Hanis Abdul Samat, for her tremendous help during my ups and down while doing the labwork, Sr. Syazana Zahri and Sr. 'Afif Raihan Abdullah for their help and support as my team mates, Assistant Prof. Dr. Norazsida Ramli and Assistant Prof. Dr. Nurulwahida Saad for their assistance in statistical analysis, Assistant Prof. Dr. Wisam Nabeel Ibrahim, Associate Prof. Dr. Ibrahim Shogar and Sr. Ayah Hilles for their assistance in the write up of the Arabic abstracts, Br. Hanif, Sr. Wan Noorulkhamisa and Sr. Nadzirah, the Medical Lab Technologist in Histopathology Research Laboratory, Kulliyyah of Medicine (KOM), IIUM, all colleagues, post-graduates sisters and staffs in Kulliyyah Allied Health Sciences, IIUM especially those in Department of Biomedical Science (Br. Azril, Br. Afif, Br. Khamzah and Sr. Farhana) for their kind assistance and technical support during my study.

Special thanks to the final year students, Sr. Syamimi, Sr. Syamim, Sr. Jaedah, Br. Jazli, Br. Haziq, Sr. Lyiana and Sr. Syafiqah, for being helpful.

I would like to acknowledge Bahagian Pembangunan Herba (HDD), the Ministry of Agriculture and Agro-based Industries (MOA) for providing the grant (NH1014D039) and Ministry of Higher Education (MOHE) for providing me financial support (Basiswa MyPhD) to accomplish the study.

Finally, I most gratefully acknowledge my deepest and special thanks to my beloved husband and sons, my parents and elder sister for their understanding, patience and continuous encouragement and support throughout the period of my study.

# TABLE OF CONTENTS

Abstract .....	ii
Abstract in Arabic .....	iii
Approval Page .....	iv
Declaration .....	v
Copyright Page .....	vi
Acknowledgements .....	vii
List of Tables .....	xii
List of Figures .....	xiv
List of Abbreviations .....	xvii
<b>CHAPTER ONE: INTRODUCTION.....</b>	<b>1</b>
1.1 Background of the Study .....	1
1.2 Research Questions .....	6
1.3 Research Hypothesis .....	6
1.4 Research Objectives .....	6
1.5 Significance of The Study .....	7
<b>CHAPTER TWO: LITERATURE REVIEW.....</b>	<b>8</b>
2.1 The Use of Plants on Female Reproductive Aspects .....	8
2.1.1 General .....	8
2.1.2 Plants For Fertility Enhancement .....	9
2.2 <i>Eurycoma longifolia</i> .....	10
2.2.1 General .....	10
2.2.2 Traditional Uses.....	11
2.2.3 Chemical Compounds .....	11
2.2.4 Pharmacology and Biological Activities .....	12
2.2.5 The Standardized Extract (TAF 273) .....	13
2.3 Female Reproductive System and Function .....	16
2.3.1 Hypothalamus-Pituitary-Gonadal Axis.....	16
2.3.2 The Ovary .....	17
2.3.2.1 Steroidogenesis and Hormones of The Ovary .....	18
2.3.2.2 Folliculogenesis .....	22
2.3.3 The Reproductive Cycle and Hormonal Regulation .....	25
2.3.3.1 Menstrual Cycle.....	26
2.3.3.2 The Rat Oestrous Cycle .....	27
2.3.4 Pregnancy and Foetal Development .....	32
2.4. Exposure of Exogenous Oestrogens On Female Reproductive System and Function .....	35
2.4.1 Oestrogenic Exposure.....	35
2.4.2 The Use of Rat as Animal Model for Female Reproductive Research .....	36
2.4.2.1 Polycystic Ovarian Syndrome .....	37
2.4.2.2 Teratogenicity.....	40

<b>CHAPTER THREE: METHODOLOGY</b> .....	<b>43</b>
3.1. Material and Methods .....	43
3.1.1 Extract Preparation .....	43
3.1.2 Justification of Doses and Dosing Periods for TAF 273 .....	43
3.1.3 Experimental Animals .....	47
3.1.4 Instruments .....	47
3.1.5 Chemical and Reagents .....	48
3.1.6 Determination of Oestrous Cycle .....	50
3.1.7 Hormonal Analysis .....	50
3.1.7.1 ELISA Assay Protocol .....	51
3.1.8 Histology of the Ovary .....	52
3.1.8.1 Tissue Processing .....	52
3.1.8.2 Embedding and Sectioning .....	53
3.1.8.3 Hematoxylin and Eosin Staining .....	54
3.1.9 Immunohistochemical Staining of the Ovary .....	56
3.1.9.1 Sample Preparation .....	56
3.1.9.2 Pre-treatment .....	56
3.1.9.3 Staining .....	57
3.1.9.4 Counterstain .....	58
3.1.10 Gene Expression Analysis .....	59
3.1.10.1 Sample Homogenization .....	59
3.1.10.2 Phase Separation .....	59
3.1.10.3 RNA Isolation .....	59
3.1.10.4 RNA Clean Up .....	60
3.1.10.5 Reverse Transcription (cDNA Synthesis) .....	61
3.1.10.6 Quantitative Real-Time PCR (qPCR) .....	64
3.1.11 Teratogenicity .....	65
3.1.11.1 Maternal Evaluation .....	65
3.1.11.2 Foetus Evaluation .....	66
3.1.12 Statistical Analysis .....	66
<b>CHAPTER FOUR: EFFECTS OF TAF 273 ON NORMAL CONDITION OF FEMALE RATS</b> .....	<b>68</b>
4.1 Experimental Design .....	68
4.2. Results .....	71
4.2.1 5-day Treatment .....	71
4.2.1.1 Oestrous Cycle .....	71
4.2.1.2 Body Weights and Weight of Ovaries .....	74
4.2.1.3 Reproductive Hormone Analysis .....	75
4.2.1.4 Histology of the Ovary .....	76
4.2.2 14-day Treatment .....	79
4.2.2.1 Oestrous Cycle .....	79
4.2.2.2 Body Weight and Weight of Ovaries .....	82
4.2.2.3 Reproductive Hormone Analysis .....	83
4.2.2.4 Histology of the Ovary .....	84
4.3 Discussion .....	86

<b>CHAPTER FIVE: EFFECTS OF TAF 273 ON ABNORMAL INFERTILITY OR SUBFERTILITY CONDITION OF FEMALE RATS ....</b>	<b>97</b>
5.1 Experimental Design.....	97
5.1.1 Induction of Polycystic Ovarian Condition (PCO) .....	97
5.1.2 Treatment.....	98
5.2 Results.....	101
5.2.1 Induction of Polycystic Ovarian Condition (PCO) .....	101
5.2.1.1 Oestrous Cycle.....	101
5.2.1.2 Body Weights and Weights of Ovaries .....	102
5.2.1.3 Hormones Analysis .....	102
5.2.1.4 Histology of the Ovary .....	103
5.2.1.5 Immunohistochemical Observation of the Ovary.....	107
5.2.1.6 mRNA Expression of Steroidogenic Genes .....	109
5.2.2 Recovery of Polycystic Ovarian Condition (PCO) .....	110
5.2.2.1 Oestrous Cycle.....	110
5.2.2.2 Body Weights and Weights of Ovaries .....	113
5.2.2.3 Hormones Analysis .....	115
5.2.2.4 Histology of the Ovary .....	118
5.2.2.5 Immunohistochemical Observation of the Ovary.....	120
5.2.2.6 mRNA Expression of Steroidogenic Genes .....	124
5.3 Discussion .....	127
5.3.1 Effects of TAF 273 on Oestrous Cycle.....	129
5.3.2 Effects of TAF 273 on Body Weights and Weights of Ovaries...	131
5.3.3 Effects of TAF 273 on Reproductive Hormones .....	132
5.3.4 Effects of TAF 273 on Histology and Immunohistochemical Staining of The Ovary .....	139
5.3.5 Effects of TAF 273 on Expression of Steroidogenesis-related Genes .....	142
<b>CHAPTER SIX: EFFECTS OF TAF 273 ON FOETAL/ TERATOGENICITY IN NORMAL/SUBFERTILE CONDITION OF FEMALE RATS.....</b>	<b>152</b>
6.1 Experimental Design.....	152
6.2 Results.....	154
6.2.1 Maternal Body Weights.....	154
6.2.2 Post-implantation Loss and Resorption.....	155
6.2.3 Number of Live Foetuses .....	157
6.2.4 Weight of Foetuses .....	158
6.2.5 Crown-rump Length and Tail Length.....	159
6.2.6 Sex of Foetus .....	161
6.2.7 External Malformations of the Foetuses.....	162
6.3 Discussion .....	169
<b>CHAPTER SEVEN: CONCLUSION AND FUTURE WORK.....</b>	<b>181</b>
7.1 Conclusion .....	181
7.2 Limitation.....	184
7.3 Future Work .....	184
<b>REFERENCES.....</b>	<b>186</b>

<b>APPENDIX A: SCHEMATIC DIAGRAM OF THE EXPERIMENTAL DESIGN .....</b>	<b>220</b>
<b>APPENDIX B: LIST OF PUBLICATIONS AND PAPERS PRESENTED ....</b>	<b>221</b>
<b>APPENDIX C: FRONT PAGE OF PUBLICATION I.....</b>	<b>222</b>
<b>APPENDIX D: FRONT PAGE OF PUBLICATION II.....</b>	<b>223</b>
<b>APPENDIX E: PICTURES OF PROJECTS .....</b>	<b>224</b>
<b>APPENDIX F: ETHICS APPROVAL.....</b>	<b>227</b>
<b>APPENDIX G: SUPPLEMENTARY DATA FOR CHAPTER 5 (POLYCYSTIC OVARIAN SYNDROME).....</b>	<b>229</b>
<b>APPENDIX H: CERTIFICATE OF APPRECIATION FOR ORAL PRESENTATION ICAST 2015.....</b>	<b>230</b>
<b>APPENDIX I: CERTIFICATE OF APPRECIATION FOR POSTER PRESENTATION AHSC/KRW 2016.....</b>	<b>231</b>
<b>APPENDIX J: CERTIFICATE OF ACHIEVEMENT FOR HISTOLOGY WORKSHOP 2016.....</b>	<b>232</b>
<b>APPENDIX K: CERTIFICATE OF ATTENDANCE FOR BASIC IMMUNOHISTOCHEMISTRY WORKSHOP 2016 .....</b>	<b>233</b>

## LIST OF TABLES

<u>Table No.</u>		<u>Page No.</u>
2.1	Comparative Reproductive and Placental Features in Selected Experimental Mammals and Human	34
2.2	Diagnostic Criteria For Polycystic Ovarian Syndrome	39
3.1	The List of Instruments Used in The Study	47
3.2	The List of Chemicals and Reagents Used in The Study	48
3.3	The Procedure of Tissue Processing	53
3.4	Hematoxylin and Eosin Staining Procedure	55
3.5	Antibodies Used in The Experiment	58
3.6	Genomic DNA Removal Reaction Components	62
3.7	Reverse-Transcription Reaction Components	62
3.8	gDNA Elimination and RT Temperature Protocol	63
3.9	Reaction Setup	64
3.10	Real-time Cyclor Conditions	65
4.1	Effects of TAF 273 Extract Administered for 5-day on The Duration of Oestrous Cycle in Different Groups of Rats	72
4.2	Effects of TAF 273 Extract on Body Weights and Weights of Ovaries in Female Rats	74
4.3	Effects of TAF 273 Extract on Reproductive Hormones of Female Rats	75
4.4	Effects of TAF 273 Extract Administered for 14-day on The Duration of Oestrous Cycle in Different Groups of Rats	80
4.5	Effects of TAF 273 Extract on Body Weights and Weights of Ovaries in Female Rats	82
4.6	Effects of TAF 273 Extract on Reproductive Hormones of Female Rats	83
5.1	Body Weights and Weights of Ovaries 60-day Post Estradiol Valerate Induction	102

5.2	Reproductive Hormones Levels 60-day Post Estradiol Valerate Induction	102
5.3	Effects of TAF 273 Extract Administered for 28-day on The Duration of Oestrous Cycle in non-induced Female Rats	112
5.4	Body Weights and Weights of Ovaries of Female Rats after 28-day Treatment with TAF 273 Extract	113
5.5	Reproductive Hormones Levels in Female Rats after 28-day Treatment with TAF 273 Extract	115

## LIST OF FIGURES

<u>Figure No.</u>		<u>Page No.</u>
2.1	Photograph of <i>Eurycoma longifolia</i>	11
2.2	The Chemical Structures of Four Major Quassinoids	14
2.3	The Female Hypothalamus-Pituitary-Gonadal (HPG) Axis	17
2.4	Schematic Representation of The Ovarian Structure	18
2.5	Steroidogenesis in The Ovary Occurred in Theca and Granulosa Cell	20
2.6	Folliculogenesis in The Ovary	25
2.7	Overview of Events Occurs During Menstrual Cycle in Human	27
2.8	The Characteristic of Oestrous Cycle Based on The Age of Rats	28
2.9	Microscopic Observations on Types of Cells (A-C) in The Vaginal Smears of Female Rats According to Each Stage of Oestrous Cycle	30
2.10	Vaginal Smears Sequences for A 4-day and 5-day Oestrous Cycle in Female Rats	31
2.11	Hormonal Changes of Oestradiol, Progesterone, LH and FSH Throughout The Reproductive Cycle	32
2.12	Fetal Development Charts in Human Showing Period of The Ovum, Period of The Embryo and Period of The Fetus	33
4.1	Flow Chart of Study Design for 5-day Treatment	69
4.2	Flow Chart of Study Design for 14-day Treatment	70
4.3	Vaginal Smears From Female Rats Stained With Methylene Blue	73
4.4	Cross Sections of The Ovaries for 5-day Treatment Showing Normal Appearance of The Ovary and The Development of Different Stages of Follicles	77
4.5	Close Up of The Ovary Showing Different Types of Follicles	78
4.6	The Vaginal Smears of Rats Showing Transition of Cells	81
4.7	Cross Sections of The Ovaries for 14-day Treatment Showing Normal Appearance of The Ovary and The Development of Different Stages of Follicles	85

5.1	Schematic Representation On The Study Design For Induction of PCO and Treatment with TAF 273 Extract	98
5.2	Flow Chart of The Study Design	100
5.3	The Vaginal Smears of Rats Showing Vaginal Cornification With The Presence of Microphage	101
5.4	Histology of The Ovary for (a) Control and (b) EV-induced Group After 60-day of Induction	104
5.5	Close Up of The Ovary of Control Group Showing Different Types of Follicles	105
5.6	Close Up of The Ovary For EV-induced Group After 60-day of Induction	106
5.7	Immunohistochemical Staining of CYP11A1, CYP17A1, CYP19A1 and Rabbit IgG in Granulosa and Thecal Cells of A Follicle	108
5.8	mRNA Expression of CYP11A1, CYP17A1 and CYP19A1 For Control and EV-induced Group 60-day Post Induction	109
5.9	Percentage of Recovery of Female Rats After 28-day Treatment with TAF 273 Extract and Clomiphene Citrate	110
5.10	Histology of The Ovaries Following 28-day Treatment With TAF 273 Extract	119
5.11	Immunohistochemical Staining of CYP11A1, CYP17A1, CYP19A1 and Rabbit IgG in NC, P-C and P-CC Groups	121
5.12	Immunohistochemical Staining of CYP11A1, CYP17A1, CYP19A1 and Rabbit IgG in P-TA25, P-TA50 and P-TA100 Groups	122
5.13	Immunohistochemical Staining of CYP11A1, CYP17A1, CYP19A1 and Rabbit IgG in TA25, TA50 and TA100 Groups	123
5.14	mRNA Expression of CYP11A1 Gene After 28-day Treatment With TAF 273 Extract and Clomiphene Citrate	124
5.15	mRNA Expression of CYP17A1 Gene After 28-day Treatment With TAF 273 Extract and Clomiphene Citrate	125
5.16	mRNA Expression of CYP19A1 Gene After 28-day Treatment With TAF 273 Extract and Clomiphene Citrate	126
6.1	Flow Chart of Study Design	153
6.2	Maternal Body Weight on GD21 Following Exposure to EV on GD12 and Treatment with TAF 273 Extract From GD12-GD19	154

6.3	Percentages of Post-Implantation Loss and Number of Resorption Following Exposure to EV on GD12 and Treatment with TAF 273 Extract from GD12-GD19	155
6.4	Number of Live Foetuses Recovered Following Exposure to EV on GD12 and Treatment With TAF 273 Extract From GD12-GD19	157
6.5	Weight of Foetuses Following Exposure to EV on GD12 and Treatment With TAF 273 Extract From GD12-GD19	158
6.6	Crown-rump Length and Tail Length of Foetuses Following Exposure to EV on GD12 and Treatment With TAF 273 Extract From GD12-GD19	159
6.7	Sex of Foetus Following Exposure to EV on GD12 and Treatment With TAF 273 Extract From GD12-GD19	161
6.8	Observations of External Morphology of Foetuses Following Exposure to EV on GD12 and Treatment with TAF 273 Extract from GD12-GD19	162
6.9	Photograph of Representative of Foetus From Control, EV and TAF 273-Treatment Group	164
6.10	Photograph of Foetuses From Negative Control Group	164
6.11	Photograph of Foetuses From EV-induced Group	165
6.12	Photograph of Foetuses From EV-induced and Treated With 25 mg/kg TAF 273 Extract Group	165
6.13	Photograph of Foetuses From EV-induced and Treated With 50 mg/kg TAF 273 Extract Group	166
6.14	Photograph of Foetuses From EV-induced and Treated With 100 mg/kg TAF 273 Extract Group	166
6.15	Photograph showing (a) Normal Foetus and (b) Foetus With Kyphosis	167
6.16	Photograph Showing (a) Normal Foetus and (b) Foetus With Scoliosis	167
6.17	Photograph Showing (a) Foetus With Normal Tail and (b) Foetus With Kinky Tail	168
6.18	Photograph Showing (a) Foetus With Normal Growth and (b) Foetus With Inhibition of Growth	168

## LIST OF ABBREVIATIONS

AES	Androgen Excess Society
AFP	Anti-estrogen Alpha-fetoprotein
AMT	Amitriptyline
ASRM	American Society of Reproductive Medicine
$\beta$ 2AR	$\beta$ 2-adrenergic receptor
BPA	Bisphenol A
BSA	Bovine Serum Albumin
CC	Clomiphene citrate
cDNA	Complementary Deoxyribonucleic Acid
CL	Corpus Luteum
CREM	cAMP Responsive Element Modulator
CRL	Crown-rump Length
CVM	Congenital Vertebral Malformations
CYP11A1	Cholesterol Side-chain Cleavage
CYP17A1	17 $\alpha$ -hydroxylase/17, 20-lyase
CYP19A1	Aromatase
D	Dioestrus
DAB	3, 3'-diamino benzidine
DDT	Diphenyl-dichloro-trichloroethane
DES	Diethylstilbestrol
DF	Developing Follicle
DHEA	Dehydroepiandrosterone
DHEAS	3-sulfoconjugate dehydroepiandrosterone
DHT	Dihydrotestosterone
EDCs	Endocrine Disruptor Chemicals
E1	Estrone
E2	Oestradiol
E3	Estriol
EE2	17alpha-ethynilestradiol
ELISA	Enzyme-linked Immunosorbent Assay
ED	13 $\alpha$ , 21-dihydroeurycomanone
EL	Eurycomanol
EN	Eurycomanone
EP	13 $\alpha$ (21)-epoxyeurycomanone
ER	Oestrogen Receptor
ESHRE	European Society of Human Reproduction and Embryology
EV	Estradiol Valerate
FSH	Follicle Stimulating Hormone
gDNA	Genomic DNA
GD	Gestation Day
GF	Graafian Follicle
GnRH	Gonadotropin-releasing Hormone
H&E	Hematoxylin and Eosin Stains
HIER	Heat Induced Epitope-Retrieval

HPG	Hypothalamus-Pituitary-Gonadal Axis
HPLC	High Performance Liquid Chromatography
HRP	Horse Radish Peroxidase
HRT	Hormone Replacement Therapy
HSD17B	17 $\beta$ -hydroxysteroid Dehydrogenase
HSD3B1	3 $\beta$ -hydroxysteroid Dehydrogenase
ICRACU	Integrated Centre for Research Animal Care and Use
IHC	Immunohistochemistry
IGFBP1	Insulin-like growth factor-binding protein 1
I.P	Intraperitoneal
IQR	Interquartile Range
IUGR	Intrauterine Growth Restriction
IVF	In Vitro Fertilization
LD <sub>50</sub>	Median Lethal Dose
LH	Luteinizing Hormone
M	Metooestrus
mRNA	Messenger Ribonucleic Acid
NaCl	Sodium Chloride
NIH	National Institute of Health
NKEA	National Key Economic Areas
NOAEL	No-observed Adverse Effect Level
OE	Oestrus
OECD	Organisation for Economic Co-operation and Development
P	Pro-oestrus
P450 <sub>scc</sub>	Cholesterol Side-chain Cleavage Cytochrome P450 Enzyme
PAPP-A	Pregnancy-associated Plasma Protein-A
PBS	Phosphate Buffer Saline
PCB	Polychlorinated Biphenyl
PCO	Polycystic Ovarian Condition
PCOS	Polycystic Ovarian Syndrome
PCR	Polymerase Chain Reaction
PE	Persistent Oestrus
qPCR	Quantitative Polymerase Chain Reaction
RNA	Ribonucleic Acid
SD	Standard Deviation
SEM	Standard Error Mean
SGA	Small-age for Gestation
SPSS	Statistical Package for Social Sciences
StAR	Steroid Acute Regulatory Protein
TAF 273	Quassinoids-rich, Standardized Extract
TAG	Triacylglycerol
VLBW	Very Low Birth Weight
WHO	World Health Organisation

# CHAPTER ONE

## INTRODUCTION

### 1.1 BACKGROUND OF THE STUDY

The female reproductive system is strictly regulated by sex steroids and the gonadotropins which are under the control of the hypothalamus-pituitary-axis (HPG) axis through feedback mechanism (Alexander & Cotanch, 1980). The balance of sex steroids and the gonadotropins are vital for normal reproductive function and sexual development as well as for successful pregnancy (Bates & Bowling, 2013; Carreau, Wolczynski, & Galeraud-Denis, 2010). Any disruptions in the delicate balance of these hormones may not only affect fertility and complicate pregnancy but cause adverse effects on the developmental of the offspring (Alexander & Cotanch, 1980). Infertility is one of the most common reproductive disorders in both men and women of reproductive age associated with impairment in hormonal balance. Around 80 to 90% couples worldwide are affected by infertility and unable to get pregnant after 1 year of unprotected sexual intercourse. Secondary infertility may also affect couples who failed to have successful second pregnancy or subsequent child (WHO, 1983).

Oestrogen is the main female sex hormone which is produced primarily in the ovaries. The oestrogen levels in female are under the influence of endogenous and exogenous factors. Fluctuation in oestrogen levels is normal especially during menstrual cycle and in premenopausal and menopause women (Morrison, Brinton, Schmidt, & Gore, 2006; Somerville, 1971) However, high levels of oestrogen beyond the normal range in women at reproductive age may result in reduced sexual functions and capabilities for reproduction as well as development of diseases, reflecting a

disruption in the endocrine function (Hoyer & Keating, 2014; Kamphuis, Bhattacharya, Van Der Veen, Mol, & Templeton, 2014; Ptak, Hoffmann, & Rak, 2017). There has been a serious concern regarding the exposure of oestrogenic compounds environmentally or clinically that can interfere with endocrine system in females of reproductive age as well as during pregnancy (Hemminki, Gissler, & Toukoma, 1999; Joffe, 2003; Nielsen, Ostergaard, & Larsen, 2008). Oestrogenic compounds also known as endocrine disruptor chemicals (EDCs) was defined by U.S. Environmental Protection Agency (EPA) as a group of naturally occurring or synthetic compounds that can mimic the effects of endogenous oestrogen by interfering with the oestrogen signalling pathway from the synthesis to specific binding to the oestrogen receptors (Kavlock et al., 1996; Pelekanou & Leclercq, 2011). Examples of oestrogenic compounds that have been documented in relation to increased oestrogen levels include pesticides (e.g diphenyl-dichloro-trichloroethane, DDT), plastic contaminants (e.g. bisphenol A, BPA) and pharmaceuticals (e.g. diethylstilbestrol, DES; 17alpha-ethynilestradiol, EE2). Phytoestrogens in dietary components have also been listed as EDCs (Frye et al., 2012).

Exposure to excess exogenous oestrogen during a hormone-sensitive period in prenatal environment and neonatal as well as during childhood, puberty and adulthood can result in abnormalities and perturbation in the female reproductive system and function which may lead to infertility (Cui, Shen, & Li, 2013; Diamanti-Kandarakis et al., 2009; Hilakivi-Clarke, de Assis, & Warri, 2013; Shirwalkar, Modi, & Maitra, 2007). The high levels of oestrogen in women of reproductive age may lead to polycystic ovarian syndrome (PCOS) and endometrial cancer (Barrett & Sobolewski, 2014; Benjamin, Toles, Seltzer, & Deutsch, 1993; Kim & Chapman-Davis, 2010; Shafiee, Chapman, Barrett, Abu, & Atiomo, 2013). Meanwhile, exposure to oestrogen

during early pregnancy has since been known to cause teratogenic effects and may also be a risk factor for the development of cancer during adulthood (Abbott, Padmanabhan, & Dumesic, 2006; Behnam-Rasouli & Nikraves, 1997; Hemminki et al., 1999).

Plants have been used worldwide as an alternative remedy for treatment of various diseases owing to their therapeutic potential which is believed to have fewer side effects compared to the modern drug (George, 2011). Research in plants with beneficial effects especially in female reproductive aspects has garnered much attention to ensure their safety and efficacy for the purpose of development and production of plant-based medicines (Saxena, 2001). In Malaysia, plants such as *Labisia pumila* (*Kacip Fatimah*), *Ficus deltoidea* (*Mas cotek*), *Quercus infectoria* (*Manjakani*) and *Eurycoma longifolia* have long been consumed as traditional medicine to help restore hormonal balance in females and have also been used during postpartum period (Abdullah, Chermahini, Suan, & Sarmidi, 2013; Ramamurthy, Kumarappan, Dharmalingam, & Sangeh, 2014). However, *E. longifolia* was the least described on the potential effects on female reproductive health.

*Eurycoma longifolia* Jack (Simaroubaceae), also known as ‘Tongkat Ali’ is a plant indigenous to South-East Asian countries especially Peninsular Malaysia and Indonesia but is also cultivated throughout the tropics. *E. longifolia* has since received accolades and recognition as one of the important natural products able to assist men in problems with fertility (Bhat & Karim, 2010). It is also a known remedy of a myriad of ailments ranging from blood pressure conditions, dysentery, malaria, wound ulcer, boils, fever and fatigue. The many uses of *E. longifolia* in traditional and modern treatments are attributed mainly to the presence of secondary metabolites possessed by the plant. Phytochemical studies on *E. longifolia*, particularly from the

roots, have led to the identification, isolation and characterization of a wide array of chemical compounds including quassinoids, squalene derivatives, biphenylneolignans, tirucallane-type triterpenes, canthine-6-one, 1-carboline alkaloids (Gimlette & Thomson, 1977), eurycomaoside, eurycolactone, eurycomalactone, eurycomanone and pasakbumi-B (Bhat & Karim, 2010).

The effects of *E. longifolia* on male reproductive functions have been extensively studied and the most notable use of the plant is as an aphrodisiac for loss of sexual desires and impotence in men and enhancement of reproductive functions and parameters. Recent studies on fertility in male rats showed that eurycomanone from *E. longifolia* standardized, quassinoids-rich extract possessed the ability to enhance the production of testosterone thus leading in the improvement of spermatogenesis and enhanced fertility (Low, Das, & Chan, 2013). This was later elucidated by work on the Leydig cells that showed testosterone steroidogenesis was enhanced by aromatase and phosphodiesterase inhibition at varying concentrations of *E. longifolia* extract (Low, Choi, Wahab, Das, & Chan, 2013). Although *E. longifolia* is traditionally used by men to promote fertility and enhance sexual function, women during postpartum have also been known to consume the extract of the roots from the plant for energy restoration, vitality and enhancement of blood flow (Ismail, Ismail, & Lassa, 1999). It was also reported previously that two major compounds of the plant, eurycomanone and 13 $\alpha$ , 21-dihydroeurycomanone, show anti-oestrogenic properties against 17 $\alpha$ -ethynylestradiol (EE)-induced uterotrophy of immature rats (Teh et al., 2011). A recent study by Abdulghani et al. (2012) has shown that the standardized extract of *E. longifolia*, TAF 273, have a potential ability in restoration of the oestrous cycle of testosterone-induced polycystic ovarian syndrome in immature female rats. Despite the extensive research of the standardized extract in male, the safety and

potency of the extract in female counterpart have not been fully investigated. Little is known on the effect of the extract on female reproductive system and functions as well as in female reproductive disorders and teratogenicity in relation to exogenous oestrogenic exposure thus suggesting an avenue for further research that might have an impact on the common society.

Therefore, the current study was undertaken in order to investigate the potential effects of *Eurycoma longifolia* standardized extract (TAF 273) on female reproductive system and functions. In the first experiment (Chapter 4), investigations on possible effects of the plants on female reproductive system and functions was done by evaluation of the oestrous cycle, reproductive hormones and the histology of the ovary during 5- and 14-day treatment. The second experiment (Chapter 5) involved the investigation on potential effects of TAF 273 extract in the treatment of polycystic ovarian condition in estradiol valerate-induced rats by evaluation of the oestrous cycle, reproductive hormones, the histology and immunohistochemical staining of the ovary and mRNA expression of steroidogenic genes. The third experiment was done to explore the protective role of TAF 273 extract on estradiol valerate-induced teratogenicity in female rats by evaluation of maternal and foetal development. A better understanding on the possible effects of plant extracts on female reproductive system and functions will provide baseline information on the safety and efficacy of the plants for maintenance of female reproductive functions, improvement of interventions to preserve fertility and to assist in the development of achieving favorable reproductive outcomes with the use of plants as potential alternative treatment.

## 1.2 RESEARCH QUESTIONS

- How is the oestrous cycle and reproductive functions of female rats affected by the application of *Eurycoma longifolia* standardized extract?
- What are the underlying molecular mechanisms of the ameliorative effects of *Eurycoma longifolia* standardized extract on female reproductive disorders?
- Can *Eurycoma longifolia* standardized extract provide protective effects on foetus exposed to teratogens?

## 1.3 RESEARCH HYPOTHESES

*Eurycoma longifolia* standardized extract did not produce any adverse effects towards female reproductive functions with respect to the oestrous cycle and reproductive hormones. *E. longifolia* standardized extract also has restorative effects on the ovary through counteraction of perturbation on pathways in female rats with polycystic ovarian condition. *E. longifolia* also show protective effect on the foetus against teratogenic effects of estradiol valerate as a possible endocrine reproductive disruptor.

## 1.4 RESEARCH OBJECTIVES

The study was designed to evaluate the effects of the standardized extract, TAF 273, on female reproductive functions and disorders as well as teratogenicity in experimental female rats.

The study aimed to achieve the following objectives:

- To assess the effects of *Eurycoma longifolia* standardized extract on oestrous cycle and reproductive functions in nulliparous female rats.